Immune training therapy aims to tame multiple sclerosis
NCT ID NCT04530318
First seen Feb 20, 2026 · Last updated May 06, 2026 · Updated 9 times
Summary
This study tests a new treatment for relapsing-remitting multiple sclerosis (MS) that uses a patient's own immune cells (dendritic cells) to calm the immune system and reduce attacks. The therapy is given alongside standard MS medications. The trial involves 45 adults aged 18-65 with early-stage MS. The goal is to see if this combination can reduce brain lesions and prevent relapses over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Moisés Broggi
L'Hospitalet de Llobregat, Barcelona, Spain
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
-
Hospital de Sant Pau
Barcelona, Spain
-
Hospital del Mar
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.